Antifungal Drugs: Technologies and Global Markets

NEW YORK, Aug. 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0196570/Antifungal-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

INTRODUCTION

It should be noted that there is a strong emphasis on early research given the critical need for new and more effective medicines; hence, BCC is including a section of medicines intended for human utilization that are in the preclinical (animal) models of testing, and information on new and novel in vitro therapies. Greater than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast. We are limiting this research to therapies that depict a positive result or represent a very rare and novel approach worthy of further review from R&D groups.

Our key objective in this report is to present an in-depth analysis of the current human antifungal market and explore its future direction. In the last five years there has been a vast increase in the number of patent applications filed in this area. Between 1990 and 1999 there were six U.S. patents grantedevidence of the evolution of drug resistance and an increasing mortality rate.[1],[2]

Previously, BCC examined the antifungal market in its 2003 report, PHM029A ? The Market for Antifungal Drugs, in PHM029B ? Global Markets for Antifungal Agents and in PHM029C ? Antifungal Drugs: Technologies and Global Markets. Due to the rapidly changing market, BCC chose to reexamine the marketplace through another analysis and project its new growth potential. Additionally, PHM029A focused only on human fungal diseases and associated antifungals; PHM029B incorporated the marketplace for antifungals in the veterinary, agricultural and environmental industries; and PHM029C focused on human therapeutics with an intensive focus on human therapeutics in the developmental pipeline. PHM029D is an update of PHM029C.

INTENDED AUDIENCE

This report was prepared as a study of the global antifungal marketplace based on fungal infections and infestations with a focus on human therapeutics. Information is presented on the antifungal industry in general, pharmaceuticals and chemical agents, new technology within the market, new and novel drug applications and market-related issuesin many cases actual revenue is given for the period of 2010 and 2011, with projections of trends and compound annual growth rates (CAGRs) 2011 through 2016.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools to long-term-care facilities both public and private. It will also be of interest to biologists and those interested in the field of mycology.

STUDY GOALS AND OBJECTIVES 1

See the original post:
Antifungal Drugs: Technologies and Global Markets